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are of 41% for this surgery and 30% for this medication, the remaining would choose 
neither of these treatments. CONCLUSIONS: The majority of women with SUI would       
like to be treated for their condition. If asked about their preferences for different 
treatment strategies, they tend to favour the nature of the treatment. Still, efﬁcacy and 
price issues are also taken into account.
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OBJECTIVES: To assess the effect of conversion from MMF to EC-MPS on QoL in 
renal transplantation (RTx) recipients who need dose reduction due to GI symptoms. 
METHODS: Multicenter, open-label, MMF-controlled, 12-weeks trial. RTx patients 
taking MMF who had previously reported GI adverse events were randomized to 
EC-MPS (n  70, equimolar dose for 0–2 wk, dose optimization until maximum toler-
ated dose or 720 mg bid for 2–6 wk and maintenance dose for 6–12 wk); or continue 
MMF (n  64, same dose adjustment). Primary endpoint was Gastrointestinal Quality 
of Life Index (GIQLI); secondary endpoints were Gastrointestinal Symptom Rating 
Scale (GSRS), Psychological General Well-Being Index (PGWBI), Overall Treatment 
Effect (OTE) and optimization of doses of MPA. RESULTS: GIQLI scores were sig-
niﬁcantly better in EC-MPS groups at 12 wk (110.1 vs 97.2 points, p  0.0136). Mean 
adjusted scores were also signiﬁcantly in this group for all secondary scales used 
(GSRS: 36.3 vs 29.2 points, p  0.0017; PGWBI: 78.1 vs 72.4 points, p  0.0343). 
OTE evaluation of GI symptoms was signiﬁcantly better for the EC-MPS group 
(p  0.0145-patients and p  0.0006-physicians). The number of patients receiving 
intermediate doses of MPA (EC-MPS/720 mg–MMF/1000 mg) at 12 weeks was sig-
niﬁcantly higher in EC-MPS group (55.4% vs 27.4%, p  0.003). More patients with 
MMF were receiving low doses than with EC-MPS (35.6% vs 10.3%, p  0.0004). 
In MMF group a higher percentage of patients did not raise the dosage from baseline 
(23.5% for MMF and 8.9% for EC-MPS group, p  0.004). CONCLUSIONS: EC-
MPS improves gastrointestinal quality of life in renal transplant patients with GI 
complaints to MMF, as it allows an optimization of MPA dose without increasing 
GI-related symptom burden.
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OBJECTIVES: Elderly patients with impaired renal function or with a risk of kidney 
failure due to diabetes mellitus (DM) or with hypertension are at risk for accumulation 
of metabolites from certain opioids as well as for drug-drug interactions (DDI) because 
of their multimorbidity. The purpose of this analysis is to analyze the share of patients 
treated with opioids prone to accumulation of metabolites (e.g. morphine) or DDI via 
CYP450 (e.g. oxycodone, tramadole) in Germany. METHODS: This study was per-
formed using retrospective longitudinal aggregated patient data from the IMS Disease 
Analyzer. All patients 65 years or older with at least one diagnosis of DM (ICD10 
E10-E14), hypertension (I10-I15), renal failure (N17-N19), glomerular disease (N00-
N08) or renal tubulo-interstitial disease (N10-N16) with at least two prescriptions of 
extended-release (ER) morphine, hydromorphone, oxycodone or tramadole in 2008 
were included. The “P450 Drug Interaction Table” of the Indiana University was used 
as the source for substances with potential DDI. RESULTS: A total of 6565 patients 
aged 65 years or more with at least two ER opioids prescriptions in 2008 met the 
criteria of the high risk group for DDI and metabolite accumulation because of 
impaired renal function/ risk of kidney failure. A total of 702 (10.7%) patients from 
this group were treated with morphine, 528 (8.0)% with hydromorphone, 1.603 
(24.4%) with oxycodone, 3.732 (56.8%) with tramadole. Fifty-two percent of patients 
treated with oxycodone and 44% of those treated with tramadole concomitantly 
received a systemic therapy with a potential risk of DDI. CONCLUSIONS: The major-
ity of patients were treated with an opioid prone to accumulation of metabolites or 
DDI that can cause additional costs. For this group of patients the choice of hydro-
morphone can possibly avoid these potential complications.
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OBJECTIVES: Angiotensin converting enzyme inhibitors (ACEi) are frequently pres-       
cribed for various cardiac and renal diseases. A common side-effect of these drugs is 
a persistent dry cough. Physicians who fail to recognise a dry cough to be ACEi related 
may attemp to treat it with antitussive agents, in stead of recommended ACEi substi-
tution. Prescription behaviour in the general population considering treatment of the 
side-effect with antitussive agents has not been studied before. METHODS: Drug 
dispensing data between 2000 and 2007 were retrieved from the IADB.nl database.  
A prescription sequence symmetry analysis was used to determine whether antitussive           
agents were prescibed more often following ACEi initiation than the other way 
around. A logistic regression model was ﬁtted to determine predictors.        RESULTS: A 
total of 1054 patients were incident users of both ACEi and antitussives within a            
half-year time span. There was an excess of patients being prescibed antitussive agents 
after ACEi initiation, adjusted Sequence Ratio 2.2 (CI: 1.9–2.4). Females were more 
likely to be prescribed antitussive agents following ACEi therapy initiation, Odds 
Ratio 1.4 (CI: 1.1–1.9), age and comedications were no signiﬁcant predictors. CON-
CLUSIONS: There was a signiﬁcant and clinically relevant excess of patients receiving           
antitussives after ACEi initiation. The results suggest that cough as a side-effect of 
ACEi is not recognized as being ACEi related or is symptomatically treated with 
antitussive agents in stead of ACEi substitution. The estimated frequency of antitussive 
treatment of ACEi induced dry cough is 15%. Further results will be presented on 
cost implications of unnecassary drug use and decreased ACEi therapy compliance.
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OBJECTIVES: Primary hyperparathyroidism (PHPT) is the third most common endo-
crine disorder, with the majority changed being asymptomatic. Parathyroidectomy 
(PTX), as the only deﬁnite treatment, is available to severe PHPT (~20%). We evalu-
ated the mortality and co-morbidities in patients with PHPT with aim to estimate 
long-term impact of those untreated patients on the health care system. METHODS: 
This is a retrospective population-based cohort study. Using a unique patient identiﬁer 
in Tayside, Scotland, electronic record-linkage enabled a dataset of PHPT patients to 
be created from an algorithm of biochemistry and nuclear scan records, hospital 
admission data and community based prescriptions. Three additional datasets were 
added in order to measure the mortality and co-morbidities in comparison with the 
general population using standardised mortality/morbidity ratios (SMRs) and stan-
dardised incidence ratios (SIRs). Patients were split into ‘mild’ and ‘aggressive’ groups 
broadly following the NIH criteria for PTX. RESULTS: During the decade of 1997 
to 2006, we identiﬁed 2299 patients (70.4% female), 1683 (73.2%) as having mild 
PHPT. A third of the aggressive PHPT patients (32.8%) had undergone PTX. We 
found an increased risk of all-cause mortality (SMR: 2.58, 95% CI (2.39–2.79)) 
as well as cardiovascular and cancer related deaths (SMR: 2.49 (2.21–2.80); 3.02 
(2.60–3.48) respectively) in all patients. The risk is similar between the mild and 
the unoperated aggressive groups, but slightly reduced in the operated group. Unoper-
ated patients (both mild and aggressive) were also associated with high risk of co-
morbidities, with renal disease being the highest. Surgery signiﬁcantly improved 
patients’ health outcomes. CONCLUSIONS: The population prevalence of PHPT 
has generally increased; incidence is greater in females and increases with age. 
Mortality and morbidity are similarly higher for patients with mild and unoperated 
aggressive PHPT. Surgery may be worth recommending to all patients, and further 
study of the cost-effectiveness of surgery and chemotherapy is planned.
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OBJECTIVES: Aldosterone plays an important role in the pathophysiology of conges-
tive heart failure (CHF). Blockade of aldosterone receptors by spironolactone substan-
tially reduces risk of morbidity and mortality among patients with CHF. However, 
beneﬁts of spironolactone are potentially limited by its treatment compliance and 
adverse events proﬁle, particularly hyperkalemia and gynecomastia. The purpose of 
this study was to estimate the use of spironolactone in patients with CHF, the inci-
dence of key adverse events and patients compliance to spironolactone. METHODS: 
This study was performed using data from the Quebec provincial medical and drug 
plans (RAMQ). Data on medical and pharmaceutical services from January 2000 to 
September 2008 were obtained from the RAMQ for patients who had a diagnosis of 
CHF (ICD-9 codes  4280–4289) during that period. Relative incidence of gyneco-
mastia and hyperkalemia was estimated for users and non users of spironolactone. 
Treatment adherence was estimated for initial users of spironolactone and compared 
